3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
6
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Carcinoma, Non-Small-Cell Lung
2
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pre-menopausal Breast Cancer
1
Non-Small Cell Lunch Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Locally Advanced Solid Tumor
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Azacitidine
142
Cytarabine
109
venetoclax
94
fludarabine
35
Daunorubicin
34
Decitabine
32
Idarubicin
26
gilteritinib
24
Cyclophosphamide
21
quizartinib
15
midostaurin
15
Mitoxantrone
14
Etoposide
14
Granulocyte Colony-Stimulating Factor
12
Gemtuzumab
11
CPX-351
11
decitabine and cedazuridine drug combination
10
Drug Therapy
10
cc-486
9
Filgrastim
9
Clofarabine
9
ivosidenib
8
Injections
8
Dexamethasone
8
pevonedistat
7
fludarabine phosphate
7
AP 1903 reagent
7
posaconazole
6
magrolimab
6
glasdegib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Acute
×
NVP-BKM120
×
Clear all
NCT01833169
2018-10-19
SIGNATURE
Novartis
Phase 2
Completed
146 enrolled
17 charts